[Robot-assisted surgery on a broad front--without evidence for being cost-effective]

Area of Science:

• Surgical Innovation
• Health Technology Assessment
• Cost-Effectiveness Analysis

Background:

• Robot-assisted surgery is increasingly marketed across various surgical fields.
• Previous Health Technology Assessment (HTA) reports indicated limited patient value for robot-assisted surgery in specific procedures.
• Concerns exist regarding the rapid adoption of new surgical technologies compared to drug approval processes.

Purpose of the Study:

• To evaluate the cost-effectiveness of robot-assisted surgery.
• To assess whether increased costs associated with robot-assisted surgery are justified by enhanced patient value.
• To critically examine the introduction of new surgical technologies.

Main Methods:

• Review of existing Health Technology Assessment (HTA) reports on robot-assisted surgery.
• Analysis of cost data and patient outcome data for robot-assisted procedures.
• Comparative analysis of technology adoption frameworks for surgical devices versus pharmaceuticals.

Main Results:

• Robot-assisted surgery consistently leads to higher costs.
• Evidence supporting augmented patient value from robot-assisted surgery remains weak across multiple clinical applications.
• The current report confirms that robot-assisted surgery is not cost-efficient.

Conclusions:

• Robot-assisted surgery, despite its marketing, lacks sufficient evidence of cost-effectiveness.
• The introduction of new surgical technologies should be subject to more rigorous evaluation.
• A critical perspective on the adoption of new surgical techniques is warranted.